CorMedix (CRMD)
(Delayed Data from NSDQ)
$10.63 USD
+0.31 (3.00%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $10.71 +0.08 (0.75%) 6:42 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.63 USD
+0.31 (3.00%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $10.71 +0.08 (0.75%) 6:42 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Zacks News
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CorMedix (CRMD) delivered earnings and revenue surprises of 24.14% and 173.33%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Sectors of July & Their Top Stocks
by Sanghamitra Saha
Inside the top sectors of July and their top-performing stocks.
Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Implied Volatility Surging For CorMedix Inc (CRMD) Stock Options
by Zacks Equity Research
CorMedix Inc (CRMD) Stock looks to be lucrative to the option traders on the back of its surging implied volatility.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
CorMedix (CRMD) warrants investors' attention based on moves in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.
Implied Volatility Surging for CorMedix (CRMD) Stock Options
by Zacks Equity Research
Investors in CorMedix, Inc. (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Are Options Traders Betting on a Big Move in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix, Inc. (CRMD) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in CorMedix (CRMD) Stock?
by Zacks Equity Research
Investors in CorMedix, Inc. (CRMD) need to pay close attention to the stock based on moves in the options market lately.